You are here: Industry Insights > Ruzurgi

News List

US Food and Drug Administration sued over Ruzurgi drug approval europeanpharmaceuticalreview
June 20, 2019
Catalyst Pharmaceuticals Inc has sued the FDA to challenge the recent approval of a lower-cost rival drug.
Ruzurgi Approved for Pediatric Lambert-Eaton Myasthenic Syndrome (LEMS) drugs
June 03, 2019
Ruzurgi Approved for Pediatric Lambert-Eaton Myasthenic Syndrome (LEMS).
FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder fda
May 13, 2019
The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.
Ruzurgii Feature Drug approved for autoimmune disorder in kids of specified ages fda
May 08, 2019
The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.
FDA Approves Ruzurgi (amifampridine) for Children with Lambert-Eaton Myasthenic Syndrome drugs
May 08, 2019
The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17 years of age.
FDA Approves Ruzurgi for Children With Rare Autoimmune Disorder drugs
May 08, 2019
Ruzurgi (amifampridine) tablets are now approved to treat Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to 17 years, the U.S. Food and Drug Administration announced yesterday.